CAREDX, INC. (NASDAQ:CDNA) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On January8, 2018, CareDx, Inc. (the “Company”) issued a press release announcing certain preliminary financial results for the quarter and year ended December31, 2017. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The preliminary financial information presented in the press release is based on the Company’s current expectations and may be adjusted as a result of, among other things, completion of the audit of the Company’s financial statements as of, and for the year ended, December31, 2017.
The information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is intended to be furnished under Item 2.02 and Item 2.02 of Form 8-K and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Cautionary Note Regarding Forward-Looking Statements. This Current Report on Form 8-K and the press release furnished as Exhibit 99.1 hereto contain forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the note in the press release under the heading “Forward-Looking Statements” regarding these forward-looking statements.
| Item 2.02. | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibits are being furnished herewith:
CareDx, Inc. ExhibitEX-99.1 2 d521970dex991.htm EXHIBIT 99.1 Exhibit 99.1 Exhibit 99.1 CareDx Reports Preliminary Fourth Quarter and FY2017 Financial Results 32 Transplantation Centers Offering AlloSure BRISBANE,…To view the full exhibit click here
About CAREDX, INC. (NASDAQ:CDNA)
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.
